{
    "nctId": "NCT04067102",
    "briefTitle": "Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC",
    "officialTitle": "Albumin Bound (Nab)-Paclitaxel Combined With Carboplatin Versus Paclitaxel Combined With Carboplatin Followed by Epirubicin and Cyclophosphamide as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC)",
    "overallStatus": "WITHDRAWN",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "pathologic complete response\uff08pCR\uff09",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, aged \u2265 18 yrs and \u226470 yrs\uff1b\n* Histological confirmation of Unilateral primary invasive breast cancer, cT2-4NanyM0, planning to receive neoadjuvant chemotherapy\uff1b\n* The expression of ER\\<10%\uff0cPR \\<10% and Her-2 negative by immunohistochemical, if HER2 expression ++, further FISH test confirmed no amplification of Her-2 gene\uff1b\n* ECOG performance status 0-1\uff1b\n* LVEF\u226555%\uff1b\n* Bone marrow function: neutrophils \u2265 1.5\u00d7109/L, platelets \u2265 100\u00d7109/L, hemoglobin \u2265 90 g/L\uff1b\n* Liver and renal function\uff1aSerum creatinine \u2264 1.5x ULN\uff1bAspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 2.5x ULN\uff1bTotal bilirubin \u2264 1.5x ULN or when patients with Gilbert's syndrome \u2264 2.5x ULN\uff1b\n* The patient has good compliance with the planned treatment, understands the research process of the study and signs a written informed consent form.\n\nExclusion Criteria:\n\n* Cytotoxic chemotherapy, endocrine therapy or radiation therapy for any reason\uff1b\n* New York Heart Association (NYHA) score identifies patients with heart disease above grade II (including grade II)\uff1b\n* Patients with severe systemic infections or other serious illnesses\uff1b\n* Patients known to be allergic or intolerant to chemotherapeutic drugs or their excipients\uff1b\n* Combined with other malignant tumors or had malignant tumors other than breast cancer in the past 5 years, except for cervical carcinoma in situ and non-melanoma skin cancer that have been fully treated\uff1b\n* Women of childbearing age who are pregnant or lactating and who refuse to take appropriate contraceptive measures during the trial\uff1b\n* Participated in other experimental studies within 30 days before the first dose of study drug administration\n* Researchers judged patients who were unsuitable for this study.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}